The p53 Colorectal Cancer Trial
Treatment of Patients With Metastatic Colorectal Cancer Harboring TP53 Mutations With Dose-dense Cyclophosphamide - the p53 Colorectal Cancer Trial
Sponsor: Haukeland University Hospital
Terminated
The study was discontinued after the first pre-planned interim analysis due to insufficient response rates.
Other terminated trials from Haukeland University Hospital
This PHASE2 trial investigates Colorectal Cancer Metastatic and Colorectal Cancer Stage IV and is currently terminated or withdrawn. Haukeland University Hospital leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Feb 2021 — Dec 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2020 — Jun 2020 [monthly]
Recruiting PHASE2
-
Sep 2018 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Haukeland University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .